MY199070A - Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals - Google Patents
Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animalsInfo
- Publication number
- MY199070A MY199070A MYPI2018002212A MYPI2018002212A MY199070A MY 199070 A MY199070 A MY 199070A MY PI2018002212 A MYPI2018002212 A MY PI2018002212A MY PI2018002212 A MYPI2018002212 A MY PI2018002212A MY 199070 A MY199070 A MY 199070A
- Authority
- MY
- Malaysia
- Prior art keywords
- animals
- treatment
- inflammatory
- allergic
- diseaes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present application relates to the use of substituted indazoles for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially for treatment and/or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals. (Fig. 7)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172544 | 2016-06-01 | ||
| PCT/EP2017/062876 WO2017207481A1 (en) | 2016-06-01 | 2017-05-29 | Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY199070A true MY199070A (en) | 2023-10-12 |
Family
ID=56097024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018002212A MY199070A (en) | 2016-06-01 | 2017-05-29 | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20200216413A1 (en) |
| EP (1) | EP3464266B1 (en) |
| JP (1) | JP7004677B2 (en) |
| KR (1) | KR102547834B1 (en) |
| CN (3) | CN109219603B (en) |
| AU (1) | AU2017272505B9 (en) |
| BR (1) | BR112018074927A2 (en) |
| CA (1) | CA3025847A1 (en) |
| CL (1) | CL2018003432A1 (en) |
| CO (1) | CO2018013029A2 (en) |
| DK (1) | DK3464266T3 (en) |
| DO (1) | DOP2018000262A (en) |
| ES (1) | ES2898771T3 (en) |
| IL (1) | IL263132B (en) |
| MX (1) | MX394560B (en) |
| MY (1) | MY199070A (en) |
| PH (1) | PH12018502530A1 (en) |
| PL (1) | PL3464266T3 (en) |
| PT (1) | PT3464266T (en) |
| RU (1) | RU2743170C2 (en) |
| SG (1) | SG11201809470RA (en) |
| SI (1) | SI3464266T1 (en) |
| TW (1) | TWI781935B (en) |
| UA (1) | UA124237C2 (en) |
| WO (1) | WO2017207481A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3705B1 (en) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
| WO2017148902A1 (en) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| PL3448846T3 (en) | 2016-04-29 | 2021-12-20 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| HUE049331T2 (en) | 2016-04-29 | 2020-09-28 | Bayer Pharma AG | Synthesis of indazoles |
| CN109152771B (en) | 2016-06-01 | 2022-07-19 | 拜耳医药股份有限公司 | Use of 2-substituted indazoles for the treatment and prevention of autoimmune diseases |
| RU2743170C2 (en) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Substituted indazoles suitable for treating and preventing allergic and/or inflammatory diseases in animals |
| MX2020004155A (en) | 2017-10-19 | 2020-08-03 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals. |
| CN110835338A (en) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | Imidazopyridine derivative, preparation method and medical application thereof |
| KR20220018503A (en) | 2019-05-23 | 2022-02-15 | 더 유니버시티 오브 몬타나 | Vaccine adjuvants based on TLR receptor ligands |
| CN118146193A (en) * | 2019-09-24 | 2024-06-07 | 上海美悦生物科技发展有限公司 | An IRAK inhibitor and its preparation method and use |
| EP3800188A1 (en) | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
| JP7429032B2 (en) * | 2019-12-24 | 2024-02-07 | 学校法人順天堂 | Method for creating a non-human animal model of interstitial pneumonia |
| CN113521079A (en) * | 2020-04-20 | 2021-10-22 | 上海领泰生物医药科技有限公司 | Use of IRAK4 inhibitors for the treatment of ALI/ARDS |
| CN115300627B (en) * | 2021-05-08 | 2024-01-26 | 中南大学湘雅医院 | Application of sodium-glucose cotransporter 2 inhibitor, pharmaceutical composition and application thereof |
| CN113402499B (en) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | Sulfimide substituted indazole IRAK4 kinase inhibitor, preparation method and application |
| WO2025003988A1 (en) * | 2023-06-29 | 2025-01-02 | 동화약품주식회사 | Novel carboxamide derivative compound and pharmaceutical composition comprising same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID26795A (en) | 1998-07-01 | 2001-02-08 | Procter & Gamble | PROCESS FOR REMOVING WATER FROM NETWORKS WEIGHT USING VIBRATION POWDER GAS FLOWS |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| RU2005105683A (en) * | 2002-07-31 | 2006-01-20 | Шеринг Акциенгезельшафт (De) | POSSESSING INHIBITING ACTION ON VEGFR-2 AND VEGFR-3 ANTHRANILAMIDOPYRIDINES |
| CA2531543C (en) | 2003-06-25 | 2010-10-12 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| WO2005082866A2 (en) | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| WO2006061715A2 (en) | 2004-12-08 | 2006-06-15 | Warner-Lambert Company Llc | Methylene inhibitors of matrix metalloproteinase |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| GT200600411A (en) | 2005-09-13 | 2007-05-21 | Novartis Ag | COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR |
| HUE025173T2 (en) | 2005-12-13 | 2016-01-28 | Incyte Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| BRPI0707718A2 (en) | 2006-02-10 | 2011-05-10 | Summit Corp Plc | use of a compound |
| EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| US7879887B2 (en) | 2006-06-29 | 2011-02-01 | Nissan Chemical Industries, Ltd. | α-amino acid derivatives and medicaments containing the same as an active ingredient |
| EP2061786A2 (en) | 2006-09-07 | 2009-05-27 | Biogen Idec MA Inc. | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| US20140113898A1 (en) | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| WO2012078674A1 (en) | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted indole/indazole-pyrimidinyl compounds |
| EP2655357B1 (en) | 2010-12-20 | 2016-06-22 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| CN103402985A (en) | 2011-02-10 | 2013-11-20 | 先正达参股股份有限公司 | Microbiocidal pyrazole derivatives |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| HUE026893T2 (en) | 2012-02-21 | 2016-07-28 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| CA2873975A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
| WO2015017336A1 (en) * | 2013-07-29 | 2015-02-05 | OmniGen Research, L.L.C. | Combination and method for administration to an animal |
| TWI667233B (en) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments |
| HK1231480A1 (en) * | 2014-01-10 | 2017-12-22 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| JP2017518348A (en) | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Substituted indazole compounds as IRAK4 inhibitors |
| CN104093061B (en) * | 2014-07-18 | 2020-06-02 | 北京智谷睿拓技术服务有限公司 | Content sharing method and device |
| JO3705B1 (en) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
| WO2016174183A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| HUE049331T2 (en) * | 2016-04-29 | 2020-09-28 | Bayer Pharma AG | Synthesis of indazoles |
| PL3448846T3 (en) * | 2016-04-29 | 2021-12-20 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| CN109152771B (en) | 2016-06-01 | 2022-07-19 | 拜耳医药股份有限公司 | Use of 2-substituted indazoles for the treatment and prevention of autoimmune diseases |
| RU2743170C2 (en) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Substituted indazoles suitable for treating and preventing allergic and/or inflammatory diseases in animals |
-
2017
- 2017-05-29 RU RU2018145860A patent/RU2743170C2/en active
- 2017-05-29 CN CN201780034405.9A patent/CN109219603B/en active Active
- 2017-05-29 CA CA3025847A patent/CA3025847A1/en active Pending
- 2017-05-29 KR KR1020187034447A patent/KR102547834B1/en active Active
- 2017-05-29 PL PL17725976T patent/PL3464266T3/en unknown
- 2017-05-29 BR BR112018074927-3A patent/BR112018074927A2/en not_active Application Discontinuation
- 2017-05-29 EP EP17725976.9A patent/EP3464266B1/en active Active
- 2017-05-29 AU AU2017272505A patent/AU2017272505B9/en active Active
- 2017-05-29 UA UAA201812729A patent/UA124237C2/en unknown
- 2017-05-29 SG SG11201809470RA patent/SG11201809470RA/en unknown
- 2017-05-29 ES ES17725976T patent/ES2898771T3/en active Active
- 2017-05-29 WO PCT/EP2017/062876 patent/WO2017207481A1/en not_active Ceased
- 2017-05-29 JP JP2018563160A patent/JP7004677B2/en active Active
- 2017-05-29 PT PT177259769T patent/PT3464266T/en unknown
- 2017-05-29 SI SI201730981T patent/SI3464266T1/en unknown
- 2017-05-29 CN CN202411527831.4A patent/CN119367364A/en active Pending
- 2017-05-29 DK DK17725976.9T patent/DK3464266T3/en active
- 2017-05-29 MY MYPI2018002212A patent/MY199070A/en unknown
- 2017-05-29 US US16/306,235 patent/US20200216413A1/en not_active Abandoned
- 2017-05-29 CN CN202510679871.9A patent/CN120531733A/en active Pending
- 2017-05-29 MX MX2018014899A patent/MX394560B/en unknown
- 2017-06-01 TW TW106118035A patent/TWI781935B/en active
-
2018
- 2018-11-19 IL IL263132A patent/IL263132B/en unknown
- 2018-11-29 PH PH12018502530A patent/PH12018502530A1/en unknown
- 2018-11-30 DO DO2018000262A patent/DOP2018000262A/en unknown
- 2018-11-30 CO CONC2018/0013029A patent/CO2018013029A2/en unknown
- 2018-11-30 CL CL2018003432A patent/CL2018003432A1/en unknown
-
2022
- 2022-01-07 US US17/570,550 patent/US12459916B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502530A1 (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| IL255203B (en) | Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| SI3377637T1 (en) | Compositions for use in procedures for the treatment of wounds, disorders and skin diseases | |
| KR20230104752A9 (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| PH12019550265A1 (en) | Composition comprising mannose oligosaccharide and process for making same and use thereof | |
| WO2015197193A3 (en) | New use for jnk inhibitor molecules for treatment of various diseases | |
| MX379359B (en) | DERIVATIVES OF 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECane. | |
| MX2019014935A (en) | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses. | |
| EP3582768A4 (en) | CANNABINOID FORMULATIONS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| EP4574832A3 (en) | Dantrolene prodrugs and methods of their use | |
| IL266619A (en) | Treatment of respiratory tract diseases and infections with ascorbic acid compositions | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| WO2018081183A3 (en) | Maca compositions and methods of use | |
| MX2018000092A (en) | New bicyclic lipolantipeptide, preparation and use as antimicrobial agent. | |
| PH12020550444A1 (en) | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals | |
| JP2015508052A5 (en) | ||
| IL268271A (en) | Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals | |
| PH12017500743A1 (en) | Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency | |
| MX2020001501A (en) | Streptococcus australis as a biotherapeutics. | |
| GB2550750A (en) | Anthelmintic compounds | |
| WO2017142368A3 (en) | Composition for preventing and treating allergic or inflammatory skin disease | |
| HK1230969A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |